Exploring the anti‐inflammatory activity of sulforaphane

Treasure, Katie; Harris, James; Williamson, Gary

doi:10.1111/imcb.12686

Cited by 10 publications

(4 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these experimental model systems, tBHQ treatment partially alleviated, whereas Nrf2 or AHSP knockdown exacerbated, α-globin precipitation and ROS production in fetal liver-derived thalassemic erythroid cells. In this context, it should be mentioned that sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, has received attention as a natural activator of the Nrf2/Keap1 cytoprotective pathway [ 84 ]. Other NRF2 activators have been reported and recently reviewed [ 85 , 86 ].…”

Section: Inducers Of Alpha-hemoglobin-stabilizing Proteinmentioning

confidence: 99%

Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management

Traeger-Synodinos,

Vrettou,

Sofocleous

et al. 2024

IJMS

View full text Add to dashboard Cite

In this short review, we presented and discussed studies on the expression of globin genes in β-thalassemia, focusing on the impact of α-globin gene expression and α-globin modifiers on the phenotype and clinical severity of β-thalassemia. We first discussed the impact of the excess of free α-globin on the phenotype of β-thalassemia. We then reviewed studies focusing on the expression of α-globin-stabilizing protein (AHSP), as a potential strategy of counteracting the effects of the excess of free α-globin on erythroid cells. Alternative processes controlling α-globin excess were also considered, including the activation of autophagy by β-thalassemia erythroid cells. Altogether, the studies reviewed herein are expected to have a potential impact on the management of patients with β-thalassemia and other hemoglobinopathies for which reduction in α-globin excess is clinically beneficial.

show abstract

Section: Inducers Of Alpha-hemoglobin-stabilizing Proteinmentioning

confidence: 99%

Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management

Traeger-Synodinos,

Vrettou,

Sofocleous

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Sulforaphane is characterized by an electrophilic central carbon, which is part of the isothiocyanate group and can react with cysteine residues from other molecules and facilitate interactions with important signaling mediators [ 133 ] such as Nrf2, NF-κB, and inflammasome complexes.…”

Section: Glucosinolatesmentioning

confidence: 99%

Synergic Role of Dietary Bioactive Compounds in Breast Cancer Chemoprevention and Combination Therapies

Mecca,

Sichetti,

Giuseffi

et al. 2024

Nutrients

View full text Add to dashboard Cite

Breast cancer is the most common tumor in women. Chemotherapy is the gold standard for cancer treatment; however, severe side effects and tumor resistance are the major obstacles to chemotherapy success. Numerous dietary components and phytochemicals have been found to inhibit the molecular and signaling pathways associated with different stages of breast cancer development. In particular, this review is focused on the antitumor effects of PUFAs, dietary enzymes, and glucosinolates against breast cancer. The major databases were consulted to search in vitro and preclinical studies; only those with solid scientific evidence and reporting protective effects on breast cancer treatment were included. A consistent number of studies highlighted that dietary components and phytochemicals can have remarkable therapeutic effects as single agents or in combination with other anticancer agents, administered at different concentrations and via different routes of administration. These provide a natural strategy for chemoprevention, reduce the risk of breast cancer recurrence, impair cell proliferation and viability, and induce apoptosis. Some of these bioactive compounds of dietary origin, however, show poor solubility and low bioavailability; hence, encapsulation in nanoformulations are promising tools able to increase clinical efficiency.

show abstract

“…ITCs have been shown to modulate the tumor microenvironment, thereby affecting cancer cell behavior ( 31 , 40 ). For instance, ITCs can modify the inflammatory response within the tumor microenvironment, which may contribute to their anticancer effects ( 39 , 46 ).…”

Section: Introductionmentioning

confidence: 99%

Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management

Wang,

Li,

Liu

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

Human studies have shown the anticancer effects of dietary isothiocyanates (ITCs), but there are some inconsistencies, and more evidence supports that such anticancer effect is from higher doses of ITCs. The inconsistencies found in epidemiological studies may be due to many factors, including the biphasic dose–response (so called hormetic effect) of ITCs, which was found to be more profound under hypoxia conditions. In this comprehensive review, we aim to shed light on the intriguing synergistic interactions between dietary ITCs, focusing on sulforaphane (SFN) and various anticancer drugs. Our exploration is motivated by the potential of these combinations to enhance cancer management strategies. While the anticancer properties of ITCs have been recognized, our review delves deeper into understanding the mechanisms and emphasizing the significance of the hormetic effect of ITCs, characterized by lower doses stimulating both normal cells and cancer cells, whereas higher doses are toxic to cancer cells and inhibit their growth. We have examined a spectrum of studies unraveling the multifaceted interaction and combinational effects of ITCs with anticancer agents. Our analysis reveals the potential of these synergies to augment therapeutic efficacy, mitigate chemoresistance, and minimize toxic effects, thereby opening avenues for therapeutic innovation. The review will provide insights into the underlying mechanisms of action, for example, by spotlighting the pivotal role of Nrf2 and antioxidant enzymes in prevention. Finally, we glimpse ongoing research endeavors and contemplate future directions in this dynamic field. We believe that our work contributes valuable perspectives on nutrition and cancer and holds promise for developing novel and optimized therapeutic strategies.

show abstract

Exploring the anti‐inflammatory activity of sulforaphane

Cited by 10 publications

References 210 publications

Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management

Impact of α-Globin Gene Expression and α-Globin Modifiers on the Phenotype of β-Thalassemia and Other Hemoglobinopathies: Implications for Patient Management

Synergic Role of Dietary Bioactive Compounds in Breast Cancer Chemoprevention and Combination Therapies

Dietary isothiocyanates and anticancer agents: exploring synergism for improved cancer management

Contact Info

Product

Resources

About